Supercomputer-Based Virtual Screening for Deoxyribonucleic Acid Methyltransferase 1 Inhibitors As Novel Anticancer Agents

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Nov 27

PMID 39595939

Authors

Lara Johanna Friedrich

Axel Guthart

Min Zhou

Paola B Arimondo

Thomas Efferth

Mona Dawood

Affiliations

Soon will be listed here.

Abstract

Targeting epigenetics is a new strategy to treat cancer and develop novel epigenetic drugs with anti-tumor activity. DNA methyltransferases transfer the methyl group from -adenosyl-L-methionine (SAM) to the cytosine residue in a CpG island, leading to the transcription silencing of the gene. Hypermethylation can frequently be observed in several tumor types. Hence, the inhibition of DNMT1 has become a novel approach to cure cancer. In this study, virtual screening and molecular docking were performed for more than 11,000 ligands from the ZINC15 database to discover new hypomethylation agents. Four candidate compounds were further tested for their effects on DNMT1 in silico and in vitro. Compounds and showed the best DNMT1 inhibitory activity, but only compound was able to inhibit the growth of several cancer cell lines. The hypomethylation of the luciferase gene by compound was verified by a - luciferase assay using KG-1 cells. Additionally, compound suppressed cell migration in a dose- and time-dependent manner in the wound healing assay. Moreover, cell cycle analyses demonstrated that compound arrested CCRF-CEM cells and MDA-MB-468 cells in the G0/G1 phase. Also, compound significantly induced early and late apoptosis in a dose-dependent manner. In conclusion, we introduce compound as a novel DNMT1 inhibitor with anticancer activity.

References

Pappalardi M, Keenan K, Cockerill M, Kellner W, Stowell A, Sherk C . Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021; 2(10):1002-1017. PMC: 8594913. View

Phillips J, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E . Scalable molecular dynamics with NAMD. J Comput Chem. 2005; 26(16):1781-802. PMC: 2486339. DOI: 10.1002/jcc.20289. View

Nasrullah , Hussain A, Ahmed S, Rasool M, Shah A . DNA methylation across the tree of life, from micro to macro-organism. Bioengineered. 2022; 13(1):1666-1685. PMC: 8805842. DOI: 10.1080/21655979.2021.2014387. View

Erdmann A, Halby L, Fahy J, Arimondo P . Targeting DNA methylation with small molecules: what's next?. J Med Chem. 2014; 58(6):2569-83. DOI: 10.1021/jm500843d. View

Dagogo-Jack I, Shaw A . Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2017; 15(2):81-94. DOI: 10.1038/nrclinonc.2017.166. View

Iyer L, Abhiman S, Aravind L . Natural history of eukaryotic DNA methylation systems. Prog Mol Biol Transl Sci. 2011; 101:25-104. DOI: 10.1016/B978-0-12-387685-0.00002-0. View

Kort E, Jovinge S . Drug Repurposing: Claiming the Full Benefit from Drug Development. Curr Cardiol Rep. 2021; 23(6):62. DOI: 10.1007/s11886-021-01484-5. View

Kadioglu O, Cao J, Kosyakova N, Mrasek K, Liehr T, Efferth T . Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistance. Sci Rep. 2016; 6:36754. PMC: 5099876. DOI: 10.1038/srep36754. View

Yan L, Geng Q, Cao Z, Liu B, Lu P, Lin L . Insights into DNMT1 and programmed cell death in diseases. Biomed Pharmacother. 2023; 168:115753. DOI: 10.1016/j.biopha.2023.115753. View

10.

Schermelleh L, Spada F, Easwaran H, Zolghadr K, Margot J, Cardoso M . Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat Methods. 2005; 2(10):751-6. DOI: 10.1038/nmeth794. View

11.

Kazanets A, Shorstova T, Hilmi K, Marques M, Witcher M . Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. Biochim Biophys Acta. 2016; 1865(2):275-88. DOI: 10.1016/j.bbcan.2016.04.001. View

12.

Lakshminarasimhan R, Liang G . The Role of DNA Methylation in Cancer. Adv Exp Med Biol. 2016; 945:151-172. PMC: 7409375. DOI: 10.1007/978-3-319-43624-1_7. View

13.

Khader A, Bokhari R, Hakimelahi R, Scheirey C, Afnan J, Braschi-Amirfarzan M . A radiologist's guide to novel anticancer therapies in the era of precision medicine. Eur J Radiol Open. 2022; 9:100406. PMC: 8899228. DOI: 10.1016/j.ejro.2022.100406. View

14.

Perri F, Pisconti S, Della Vittoria Scarpati G . P53 mutations and cancer: a tight linkage. Ann Transl Med. 2017; 4(24):522. PMC: 5233470. DOI: 10.21037/atm.2016.12.40. View

15.

Efferth T, Verdorfer I, Miyachi H, Sauerbrey A, Drexler H, Chitambar C . Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM leukemia cell lines. Blood Cells Mol Dis. 2002; 29(1):1-13. DOI: 10.1006/bcmd.2002.0530. View

16.

Zhang X, Nie Y, Zhang R, Yu J, Ge J . Reduced DNMT1 levels induce cell apoptosis via upregulation of METTL3 in cardiac hypertrophy. Heliyon. 2024; 10(3):e24572. PMC: 10837504. DOI: 10.1016/j.heliyon.2024.e24572. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Czabotar P, Lessene G, Strasser A, Adams J . Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2013; 15(1):49-63. DOI: 10.1038/nrm3722. View

19.

Humphrey W, Dalke A, Schulten K . VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33-8, 27-8. DOI: 10.1016/0263-7855(96)00018-5. View

20.

Rilova E, Erdmann A, Gros C, Masson V, Aussagues Y, Poughon-Cassabois V . Design, synthesis and biological evaluation of 4-amino-N- (4-aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation. ChemMedChem. 2014; 9(3):590-601. PMC: 4506529. DOI: 10.1002/cmdc.201300420. View